[
  {
    "ts": null,
    "headline": "Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform",
    "summary": "Hims & Hers Health  said it is expanding its weight-loss offerings with the addition of  Eli Lilly  & Co. Zepbound and generic liraglutide.  The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.  “We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said.",
    "url": "https://finnhub.io/api/news?id=eefdfe9c27a794d1da174d4d96141ac9b8d70b207e28c54c519d26cc598eb518",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743550680,
      "headline": "Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform",
      "id": 133658149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health  said it is expanding its weight-loss offerings with the addition of  Eli Lilly  & Co. Zepbound and generic liraglutide.  The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.  “We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said.",
      "url": "https://finnhub.io/api/news?id=eefdfe9c27a794d1da174d4d96141ac9b8d70b207e28c54c519d26cc598eb518"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs",
    "summary": "Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.",
    "url": "https://finnhub.io/api/news?id=e6b49f1119274156eaae4fb1b2f7d471270564dafa6c2021ad0ad101b170a933",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743543488,
      "headline": "Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs",
      "id": 133658150,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.",
      "url": "https://finnhub.io/api/news?id=e6b49f1119274156eaae4fb1b2f7d471270564dafa6c2021ad0ad101b170a933"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): The Best Healthcare Stock to Buy According to Billionaires",
    "summary": "We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best healthcare stocks to invest in. Healthcare stocks experienced a challenging year in 2024, lagging behind high-growth sectors like tech […]",
    "url": "https://finnhub.io/api/news?id=c056e161078cf9ceea195a3b699ca0af7593241ff7c97f66930f8683c663b08c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743541149,
      "headline": "Eli Lilly and Company (LLY): The Best Healthcare Stock to Buy According to Billionaires",
      "id": 133658152,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Healthcare Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best healthcare stocks to invest in. Healthcare stocks experienced a challenging year in 2024, lagging behind high-growth sectors like tech […]",
      "url": "https://finnhub.io/api/news?id=c056e161078cf9ceea195a3b699ca0af7593241ff7c97f66930f8683c663b08c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback",
    "summary": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=16c699b332de57394a58b8070aba6ae3a3bec745ff109be2aa73ba7125a2e757",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743540527,
      "headline": "Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback",
      "id": 133658154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=16c699b332de57394a58b8070aba6ae3a3bec745ff109be2aa73ba7125a2e757"
    }
  },
  {
    "ts": null,
    "headline": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
    "summary": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
    "url": "https://finnhub.io/api/news?id=53c3a03eff706b7ad16a906ef211df0bea2b8da20015bab4eb49fde725f274ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743538516,
      "headline": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
      "id": 133658155,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
      "url": "https://finnhub.io/api/news?id=53c3a03eff706b7ad16a906ef211df0bea2b8da20015bab4eb49fde725f274ee"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
    "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index dropping 2.1% an",
    "url": "https://finnhub.io/api/news?id=27dd22c7ea89dfbf74be7ad3b60e982777bb519a71dde1eec9895b61c00487f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743537650,
      "headline": "Sector Update: Health Care Stocks Fall Late Afternoon",
      "id": 133658157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index dropping 2.1% an",
      "url": "https://finnhub.io/api/news?id=27dd22c7ea89dfbf74be7ad3b60e982777bb519a71dde1eec9895b61c00487f9"
    }
  },
  {
    "ts": null,
    "headline": "Wilbur Ross Has Thoughts on Trump’s Tariffs",
    "summary": "Wilbur Ross Has Thoughts on Trump’s Tariffs",
    "url": "https://finnhub.io/api/news?id=5fdd26e14780f0077d9cc7de6cc31bc07a4e4e420a17d53954514c66107582da",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743532260,
      "headline": "Wilbur Ross Has Thoughts on Trump’s Tariffs",
      "id": 133658749,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Wilbur Ross Has Thoughts on Trump’s Tariffs",
      "url": "https://finnhub.io/api/news?id=5fdd26e14780f0077d9cc7de6cc31bc07a4e4e420a17d53954514c66107582da"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform",
    "summary": "Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo...",
    "url": "https://finnhub.io/api/news?id=d44eb5db3334183245c7e4eb96ea8d232c54bf26afa8e6095b08d0af79a35916",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743529961,
      "headline": "Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform",
      "id": 133656386,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo...",
      "url": "https://finnhub.io/api/news?id=d44eb5db3334183245c7e4eb96ea8d232c54bf26afa8e6095b08d0af79a35916"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers to sell Lilly's Zepbound on its telehealth platform",
    "summary": "The telehealth firm joins its peers such as Teladoc and LifeMD to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs.  The company said it will offer both branded versions of Lilly's tirzepatide - the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro - as well as generics of Novo Nordisk's diabetes drug, liraglutide.  Hims & Hers previously only offered cheaper versions of Novo's weight loss drug Wegovy.",
    "url": "https://finnhub.io/api/news?id=9d64c2169b2a055d7752334dd0bc17c3016b2b31cbf8ea718efa40099e3db951",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743529173,
      "headline": "Hims & Hers to sell Lilly's Zepbound on its telehealth platform",
      "id": 133655185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The telehealth firm joins its peers such as Teladoc and LifeMD to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs.  The company said it will offer both branded versions of Lilly's tirzepatide - the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro - as well as generics of Novo Nordisk's diabetes drug, liraglutide.  Hims & Hers previously only offered cheaper versions of Novo's weight loss drug Wegovy.",
      "url": "https://finnhub.io/api/news?id=9d64c2169b2a055d7752334dd0bc17c3016b2b31cbf8ea718efa40099e3db951"
    }
  },
  {
    "ts": null,
    "headline": "Statement: Lilly has no affiliation with hims & hers",
    "summary": "INDIANAPOLIS, April 1, 2025 - Eli Lilly and Company has no affiliation with hims & hers. Zepbound can be prescribed by any licensed healthcare professional. People who are commercially insured with...",
    "url": "https://finnhub.io/api/news?id=87d10d661a04fbd175e7d8f2773c5cf823c2dc92a78cda175a32a8cce6f06a89",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743528743,
      "headline": "Statement: Lilly has no affiliation with hims & hers",
      "id": 133656309,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS, April 1, 2025 - Eli Lilly and Company has no affiliation with hims & hers. Zepbound can be prescribed by any licensed healthcare professional. People who are commercially insured with...",
      "url": "https://finnhub.io/api/news?id=87d10d661a04fbd175e7d8f2773c5cf823c2dc92a78cda175a32a8cce6f06a89"
    }
  },
  {
    "ts": null,
    "headline": "Trump's Pharma Tariffs Could Blow Up Global Drug Supply Chains",
    "summary": "A 25% levy is looming--and Big Pharma's billion-dollar operations in Europe may be on the chopping block.",
    "url": "https://finnhub.io/api/news?id=804f6996d4f5fe1e72076dd07b90cf1be0fee89517693ac8ed0400ddbfb5c174",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743528148,
      "headline": "Trump's Pharma Tariffs Could Blow Up Global Drug Supply Chains",
      "id": 133655186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A 25% levy is looming--and Big Pharma's billion-dollar operations in Europe may be on the chopping block.",
      "url": "https://finnhub.io/api/news?id=804f6996d4f5fe1e72076dd07b90cf1be0fee89517693ac8ed0400ddbfb5c174"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update",
    "summary": "By Sabela Ojea Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform...",
    "url": "https://finnhub.io/api/news?id=d0493951bbf52856d464476bdc16341a387da4a8b12f6c2c770709e3b9fad28c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743527700,
      "headline": "Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update",
      "id": 133656635,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Sabela Ojea Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co.'s Zepbound and generic liraglutide. The telehealth-consultation platform...",
      "url": "https://finnhub.io/api/news?id=d0493951bbf52856d464476bdc16341a387da4a8b12f6c2c770709e3b9fad28c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=1b506907e11ea6c18bcd67be5dbb12b3e10a3d666143ee5495bc484b311b6cdb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743525060,
      "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "id": 133658750,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=1b506907e11ea6c18bcd67be5dbb12b3e10a3d666143ee5495bc484b311b6cdb"
    }
  },
  {
    "ts": null,
    "headline": "Update: Eli Lilly Reportedly Sues More Drug Compounders for Copying Weight Loss Drug",
    "summary": "(Updates with statement from Eli Lilly spokesperson in the last two paragraphs.) Eli Lilly (LLY)",
    "url": "https://finnhub.io/api/news?id=3c901a9d215a9dc9744931b58f9426051a1d4c83f91c75bc084457ff8414facd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743523243,
      "headline": "Update: Eli Lilly Reportedly Sues More Drug Compounders for Copying Weight Loss Drug",
      "id": 133655187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with statement from Eli Lilly spokesperson in the last two paragraphs.) Eli Lilly (LLY)",
      "url": "https://finnhub.io/api/news?id=3c901a9d215a9dc9744931b58f9426051a1d4c83f91c75bc084457ff8414facd"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list",
    "summary": "Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter.",
    "url": "https://finnhub.io/api/news?id=4ec367cf4224a39d8f68e6b37a3b6ec3fafd62fe775cd1dc6d908a2ebf032126",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743521886,
      "headline": "Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list",
      "id": 133647105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter.",
      "url": "https://finnhub.io/api/news?id=4ec367cf4224a39d8f68e6b37a3b6ec3fafd62fe775cd1dc6d908a2ebf032126"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly is coming after makers of copycat versions of Zepbound",
    "summary": "Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.",
    "url": "https://finnhub.io/api/news?id=e1940083e6d5128ca8398ffba4f1ca532db0f67768bc9c8543b78516be9f30e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743520380,
      "headline": "Eli Lilly is coming after makers of copycat versions of Zepbound",
      "id": 133655189,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=e1940083e6d5128ca8398ffba4f1ca532db0f67768bc9c8543b78516be9f30e0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Ralph Lauren included in BofA's 'Top 10 US Ideas for Q2 2025' list",
    "summary": "Investing.com -- Bank of America released its Top 10 US Ideas for Q2 2025 note on Tuesday, highlighting stocks the firm believes have significant market and business-related catalysts in the months ahead.",
    "url": "https://finnhub.io/api/news?id=44d2b4dd3b2d73af2cd91cbb3d9a48eb23905cd01f619effe375ce099143cc8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743519885,
      "headline": "Eli Lilly and Ralph Lauren included in BofA's 'Top 10 US Ideas for Q2 2025' list",
      "id": 133645202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Bank of America released its Top 10 US Ideas for Q2 2025 note on Tuesday, highlighting stocks the firm believes have significant market and business-related catalysts in the months ahead.",
      "url": "https://finnhub.io/api/news?id=44d2b4dd3b2d73af2cd91cbb3d9a48eb23905cd01f619effe375ce099143cc8d"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Gene-Editing Stock to Buy?",
    "summary": "We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to […]",
    "url": "https://finnhub.io/api/news?id=4e9ece4c290d21d659e24fee6cd3958ca86fe51413f5c4bae550909f2d27771d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743515251,
      "headline": "Is Eli Lilly and Company (LLY) the Best Gene-Editing Stock to Buy?",
      "id": 133645204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to […]",
      "url": "https://finnhub.io/api/news?id=4e9ece4c290d21d659e24fee6cd3958ca86fe51413f5c4bae550909f2d27771d"
    }
  },
  {
    "ts": null,
    "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=5c3d49a322aa5e57d425b183a4e954034f65a2cf445a486232438c6d11e2e695",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743512409,
      "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
      "id": 133645206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=5c3d49a322aa5e57d425b183a4e954034f65a2cf445a486232438c6d11e2e695"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Eli Lilly Be in 1 Year?",
    "summary": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
    "url": "https://finnhub.io/api/news?id=994d05a53c3762023e3eed311434f45215a371d4cebd355cf87da5ea912e7921",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743500220,
      "headline": "Where Will Eli Lilly Be in 1 Year?",
      "id": 133645207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
      "url": "https://finnhub.io/api/news?id=994d05a53c3762023e3eed311434f45215a371d4cebd355cf87da5ea912e7921"
    }
  }
]